Datamonitor expects a substantial increase in prevalent rheumatoid arthritis in China over the next decade. In 2011, there were approximately 3.966 million total prevalent cases of rheumatoid arthritis (RA) in China. About 53% of RA cases were among people living in rural areas. However, by 2021, 57% of RA cases will be urban.Gain insight into market potential, including a robust 10-year epidemiology forecast of RA prevalence cases in China.Understand the key epidemiologic risk factors associated with RA in China.Ability to view granular RA data to more effectively target the highest burdened patient populations.Datamonitor epidemiologists estimate that there were approximately 3.966 million total prevalent cases of rheumatoid arthritis in China in 2011.Datamonitor expects to see a dramatic increase in total prevalent cases of rheumatoid arthritis in China over the next decade.While an estimated 53% of RA cases were among people living in rural China in 2011, the number of total prevalent cases of RA in urban dwellers will increase to account for 57% of all RA cases by the end of 2021, which is a trend due to urbanization rates and rural-urban migration.How many people are there with rheumatoid arthritis in China?How will the RA patient population change over the next decade in China?What proportion of RA patients are found in rural and urban areas, and in Tier 1 and Tier 2 cities?

Table Of Contents


OVERVIEW
•Catalyst
•Summary


EXECUTIVE SUMMARY
•Disease background
•Forecast results

DISEASE DEFINITION AND DIAGNOSTIC CRITERIA •Disease definition of rheumatoid arthritis
•Common diagnostic criteria for rheumatoid arthritis

GLOBAL VARIATION AND HISTORICAL TRENDS•Global variation
•Contemporary trends - Incidence
- Prevalence

•China

DRIVERS OF RHEUMATOID ARTHRITIS EPIDEMIOLOGY•Rheumatoid arthritis is a major cause of disability
•Risk factors are largely unknown

EPIDEMIOLOGIC FORECASTING OF RHEUMATOID ARTHRITIS IN CHINA•Overview - Population denominators

•Description of methods - Sources of epidemiologic data


EPIDEMIOLOGIC RESULTS•Total prevalence of rheumatoid arthritis in China - National estimates
- Rural/urban
- Tier 1 cities
- Tier 2 cities
- Age and gender
- Age-standardized prevalence rates


DISCUSSION•Strengths and limitations of Datamonitor's epidemiologic projections


BIBLIOGRAPHY
•Journal articles
•Websites


TABLES
•Table: ACR/EULAR diagnostic criteria for rheumatoid arthritis
•Table: Examples of co-morbid conditions associated with the occurrence of RA and their level and mechanism of relationship with RA
•Table: Summary of sources used in this forecast
•Table: Economic indicators in Chinese city tiers, 2005
•Table: Total prevalent cases of rheumatoid arthritis in adults aged 25+ in China (000s), 2011-21
•Table: Total prevalent cases of rheumatoid arthritis in China, by age group, 2011


FIGURES
•Figure: Percentage of population living in urban areas in China, 1950-2020
•Figure: Total prevalent cases of rheumatoid arthritis in adults aged 25+ in China, by urban/rural (000s), 2011-21
•Figure: Total prevalent cases of rheumatoid arthritis in major cities, China, 2011-21
•Figure: Average annual growth rates of rheumatoid arthritis in China, by geographic area, 2011-21
•Figure: Total prevalent cases of rheumatoid arthritis in China, by gender, 2011
•Figure: Age-specific total prevalent cases of rheumatoid arthritis in China, 2011-21
•Figure: Age-standardized total prevalence rates of rheumatoid arthritis in China, by gender, 2011


Companies Mentioned

Aviva Plc, Fiskars Corporation, Hutchison 3G UK Limited, Schindler Holding Ltd.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Analytical Tool - Hematological Cancers

Analytical Tool - Hematological Cancers

  • $ 8 925
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.